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Abstract: In this paper, we discuss causal inference on the efficacy of a treatment or
medication on a time-to-event outcome with competing risks. Although the treatment
group can be randomized, there can be confoundings between the compliance and the
outcome. Unmeasured confoundings may exist even after adjustment for measured co-
variates. Instrumental variable (IV) methods are commonly used to yield consistent
estimations of causal parameters in the presence of unmeasured confoundings. Based
on a semi-parametric additive hazard model for the subdistribution hazard, we pro-
pose an instrumental variable estimator to yield consistent estimation of efficacy in
the presence of unmeasured confoundings for competing risk settings. We derived the
asymptotic properties for the proposed estimator. The estimator is shown to be well per-
formed under finite sample size according to simulation results. We applied our method
to a real transplant data example and showed that the unmeasured confoundings lead
to significant bias in the estimation of the effect (about 50% attenuated).
Primary 62N01, 62N02, 62P10.
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1. Introduction
In clinical trials, randomization of the treatment group can only guarantee an unbiased
estimation of the intent to treat (ITT) effect. In most cases, the true efficacy of a new
drug or treatment is of more interest. However, to yield a causal interpretation of the as-
sociation between the drug intake/treatment and the effect, we need to remove potential
confoundings between the compliance and the outcome. The assignment of treatments
and the compliance to the treatments are highly dependent on the interactions between
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the physician and the patients. It is often hard to make all confoundings controlled
by adjusting measured covariates. One important technique to handle the confound-
ing issues in causal inference is the use of instrumental variables (IV) [1], which was
first introduced in econometric literatures and then applied in the field of biomedical
sciences [2, 3]. The concept of instrumental variable had a srong influence on causal
inference studies and inspired methods such as mediation analysis [4] and Mendelian
randomization [5]. By definition, an instrumental variable is a variable that is related
to the exposure variable of interest but not directly linked to the outcome variable. For
example, researchers used children’s birthdates as an instrument to assess the effect of
education on earning [6] since this variable is correlated with years of education (the
exposure variable) but not directly associated with final earnings (the response).
In this paper, we are interested in estimating the efficacy of rituximab drug on dif-
fuse large B Cell Lymphoma (DLBCL) patients. The decision of whether to use the
drug depends on complicated factors and we are not able to fully control the treatment
process and remove the confoundings correspondingly. Since the FDA approval of rit-
uximab affects its use frequencies in clinical practice and the calendar time is highly
associated with the use of rituximab [7], we can consider the calendar time as an in-
strumental variable. This variable has an influence on the patients’ usage of rituximab,
but does not change rituximab’s drug effect.
In linear models, two commonly used instrumental variable estimators are two-stage
least squares (TSLS) [8] and generalized method of moments (GMM) [9]. The first
method is easier to implement using the existing regression softwares while the second
is potentially more efficienct when there are many instruments to use and when the
model is over-identified. To use instrumental variables in the context of time-to-event
data with censoring, Robins and Tsiatis [10] proposed an IV method to handle noncom-
pliance with the requirement that the censoring time is known (administrative censor-
ing), which was extended to proportional hazard model by Loeys and Goetghebeur[11].
IV methods that rely on other parametric model assumptions were also proposed [12].
Recently, Li et al. [13] proposed an IV based two-stage estimator for a semi-parametric
additive hazard model[14] and Chan [15] extended the TSLS method to allow exposure
dependent censoring.
Competing risks data are commonly encountered in biomedical research. In compet-
ing risks data analysis, we are often interested in studying the covariate effects on the
cumulative incidence function (CIF) of one specific cause of failure. Regression mod-
eling, such as Cox proportional hazards model, was considered as a standard approach
to model the cause-specific hazard function for each cause of failure [16, 17, 18, 19].
It is hard to summarize the covariate effects on CIF of a particular type of failure since
modeling of the cause specific hazards would result in a complex nonlinear relationship
for the CIFs. To bypass this difficulty, methods that directly model the subdistribution
hazard function of a specific cause were proposed[20, 21, 22]. However there is a gap
in handling confounding issues in competing risk data analysis. Scheike et al. [23, 24]
proposed a class of flexible regression models, including multiplicative model and ad-
ditive model for competing risks data through a direct binomial regression modeling
approach. The idea for the construction of this model is natural and it is easy to accom-
modate the model assumptions with additive model in IV analysis for the competing
risks data. To fill the gap, we extend the method of Li et al. [13] to the competing risks
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data analysis using an additive hazard subdistribution model.
In section 2, we present our proposed model followed by detailed assumptions and
estimation procedures. In section 3, the theoretical asymptotic results are provided. In
section 4, we show extensive simulation results and discuss the performance of our
proposed estimator for finite sample size compared with the simple additive hazard
model fitting without using IV. In section 5, we apply our proposed method to a real
data example and compare our results with the original fitting without using IV. In
section 6, we provide more discussions of the model and its extensions. The detailed
proofs can be found in the appendix.
2. Model
2.1. Notation
Consider a competing risk study with K types of failures. Let T and C denote the fail-
ure time and censoring time.  ∈ {1, · · · ,K} indicates the cause of failure. Consider
right censoring, we observe a composite outcome, T ∗ = min(T,C) and δ = I(T ≤
C). Denote Xe as exposure of primary interest. Denote Xo ∈ Rp and Xu ∈ Rq as
the observed and unobserved exogenous risk factors. Denote XI as the instrumental
variable. Here we begin with one dimension of Xe and one dimension of XI which fits
our motivation example. The general form with more predictors of interest and over-
identified model are discussed in later sections. Without loss of generality, we assume
that all covariates are centered at zero. Based on our notation above, our observed data
sets are {T ∗, δ, δ,Xe,Xo, XI}. Let X = {Xe,Xo,Xu, XI}, we model the cause
specific cumulative incidence function as F1(t|X) = P (T ≤ t,  = 1|X) for the
subgroup with covariate X . For notation simplicity, we treat X as time-independent.
Our method can be extended to the external time-varying covariate process (i.e. inter-
actions between time and baseline covariates) when the covariate process is available
after the event occurs. We denote Ni(t) = I(Ti ≤ t, i = 1), Yi(t) = 1 − Ni(t−).
Since Ni(t) and Yi(t) are not observable for all time points of censored subjects, we
introduce ri(t) = I(Ci ≥ Ti ∧ t), then both ri(t)Ni(t) and ri(t)Yi(t) are computable
for all time points.
2.2. Structural Additive Model for Sub-distribution Hazard
Given the important feature that for additive hazard model, the effect is collapsible over
unmeasured effects, we consider an IV analysis based on an additive subdistribution
hazard model. Suppose we are interested in cause 1, then we model the subdistribution
hazard for cause 1 as
λ1(t|X) = − d
dt
log {1− F1(t|X)} ,
our model will be in the form of
λ1(t|X) = h0(t) + βeXe + βToXo + βTuXu,
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where βe ∈ R, βo ∈ Rp and βu ∈ Rq .
Thus, we have
F1(t|X) = 1− exp
{
−
∫ t
0
λ1(s|X)ds
}
= 1− exp
{
−H0(t)− βeXet− βToXot− βTuXut
}
,
where H0(t) =
∫ t
0
h0(s)ds. So
λ1(t|Xe,Xo) = − d
dt
log {1− F1(t|Xe,Xo)}
= − d
dt
log [1− E{F1(t|X)|Xe,Xo}]
= − d
dt
log
{∫
exp
(
−H0(t)− βeXet− βToXot− βTuXut
)
dF (Xu|Xe,Xo)
}
= − d
dt
log
{
exp
(
−H0(t)− βeXet− βToXot
)∫
exp
(
−βTuXut
)
dF (Xu|Xe,Xo)
}
= h0(t) + βeXe + β
T
oXo −
d
dt
log
[
E
{
exp
(
−βTuXut
)
|Xe,Xo
}]
.
We assume E(Xu|Xo, Xe) = αeXe + αToXo and Var(Xu|Xo, Xe) = σ2uI , where
αe is a (q×1)-vector andαTo is a (q×p)-matrix. Then by second order approximation,
the above expression can be further simplified by the following approximation,
h˜0(t) + βeXe + β
T
oXo + β
T
u
(
αeXe +α
T
oXo
)
= h˜0(t) +
(
βe + β
T
uαe
)
Xe +
(
βo + β
T
uα
T
o
)
Xo
where h˜0(t) = h0(t) + β2uσ
2
ut and β
2
u = β
T
uβu. Since Xu is confounding, αe 6= 0,
thus the regression estimator for the treatment effect based on observed variables will
be biased. The above approximation holds exactly whenXu = αeXe +αToXo + eu,
with eu normally distributed and is independent of Xe andXo.
In order to obtain a consistent estimator of βe, we need to use the instrumental
variable XI . Assuming that Xe can be modeled as:
Xe = γ0 + γIXI + γ
T
oXo + γ
T
uXu + e.
We present detailed assumptions required for the instrumental variable analysis in
the following section. We denote Ri(t) = ri(t)G(t)/G(Ti ∧ t), Y ∗i (t) = Ri(t)Yi(t)
andN∗i (t) = Ri(t)Ni(t). Denote Rˆi(t) = ri(t)Gˆ(t)/Gˆ(Ti∧t), whereG(t) = P (C ≥
t) and Gˆ(t) is estimated from either Kaplan-Meier estimator when assuming random
censoring or from a specific regression model when Gi(t) = P (C ≥ t|Xoi, XIi)
depends on Xo and XI . For simplicity, only Kaplan-Meier estimate for the censoring
distribution is considered through out the paper. In practice we may consider using a
stratified Kaplan-Meier estimate when the censoring distribution is dependent of some
observed covariates. Denote Yˆi(t) = Rˆi(t)Yi(t) and Nˆi(t) = Rˆi(t)Ni(t). We assume
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that censoring distribution C is conditionally independent of (T, ) conditioning on
variables XI and Xo (Assumption 6), which is stronger than traditional assumption
thatC is conditionally independent of (T, ) conditioning on variablesXI ,Xe andXo.
This assumption is needed since Xe will not be included in the model for the second
stage of the two-stage estimator. Other assumptions are parallel to those required for
traditional additive hazard model. Thus, when Assumption 6 holds, the two models’
results are comparable.
Now we propose the two-stage estimation procedure. In the first stage, we fit a model
of Xe on XI and Xo to obtain γˆ0, γˆI and γˆ
T
o . Then compute Xˆei = γˆ0 + γˆIXIi +
γˆToXoi. In the competing risk model, we regress on Xˆei and Xoi rather than Xei and
Xoi to obtain consistent estimator βˆe. For the first stage estimator, by the result of
ordinary least square, we can estimate γˆ = (γˆ0, γˆI , γˆo)
T with
γˆ = [XTIoXIo]
−1[XTIoXe],
where XIo = [1,XI ,Xo] is a n × (p + 2) matrix. It is obvious that γˆ0, γˆI , γˆTo
are consistent estimators of γ0, γI , γTo . Thus define X˜e = XIoγ, then we have Xˆe =
XIoγˆ = XIo[X
T
IoXIo]
−1XTIoXe = HIoXe, whereHIo = XIo[X
T
IoXIo]
−1XTIo
is the projection matrix on XIo. The ordinary linear regression result guarantees that
Xˆe converge to X˜e uniformly in probability in a compact set ofXIo.
In the second stage, we fit a subdistribution additive hazard model on covariates Xˆei,
Xoi. To fit this model, we applied the estimator proposed by Sun et al. [21] and used
the R programming method developed by Scheike and Zhang [25]. We use estimated
Xˆei as our final estimator for βe. To see why this works, we make the following brief
derivation:
λ1(t|X˜ei,Xoi) = − d
dt
log
{
1− F1
(
t|X˜ei,Xoi
)}
= − d
dt
log
{
1−
∫
F1
(
t|X˜ei,Xoi,Xui, ei
)
dF
(
Xui, ei|X˜ei,Xoi
)}
.
According to the regularity conditions (see assumption 1, 4 and 5) and the fact that
F
(
Xui, ei|X˜ei,Xoi
)
= F (Xui, ei|XIi,Xoi) it can be further written as
− d
dt
log
{
1−
∫
F1
(
t|X˜ei,Xoi,Xui, ei
)
dF (Xui, ei|X˜ei,Xoi)
}
= − d
dt
log
[∫
exp
{
−H0(t)− βe
(
X˜ei + γ
T
uXui + ei
)
t− βToXoit− βTuXuit
}
dF (Xui, ei|XIi,Xoi)
]
= − d
dt
log
[∫
exp
{
−H0(t)− βeX˜eit− βeeit− βToXoit− (βTu + βeiγTu)Xuit
}
dF (Xui, ei|XIi,Xoi)
]
= − d
dt
log
[
exp
{
−H0(t)− βeX˜eit− βToXoit
}∫
exp
{
−βeieit−
(
βTu + βeγ
T
u
)
Xuit
}
dF (Xui, ei|XIi,Xoi)
]
= h∗0(t) + βeX˜ei + β
T
oXoi,
where h∗0(t) = h0(t)−
d
dt
log
[∫
exp
{
−βeeit− (βu + βeγu)TXuit
}
dF (Xui, ei|XIi,Xoi)
]
.
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Under assumption 4, with second order approximation, we have
d
dX˜e
{
− d
dt
log
[∫
exp
{
−βeeit− (βu + βeγu)TXuit
}
dF (Xui, ei|XIi,Xoi)
]}
≈ d
dX˜e
[
E[γTuXu + e|XI ,Xo]βe + V ar[γTuXu + e|XI ,Xo]β2e t
]
.
The approximation hold exactly when γTuXu + e follow normal distribution and the
quantity on the right hand side equal to 0 when γTuXu + e is mean 0 with constant
variance, which is gauranteed by assumption 1.
Denote βT = (βe,βTo). We have the following unbiased estimating equations
0 =
n∑
i=1
Ri(t)Yi(t)
{
dRi(t)Ni(t)−Ri(t)Yi(t)βT
(
X˜ei,Xoi
)
dt−Ri(t)Yi(t)dH0(t)
}
0 =
n∑
i=1
∫ τ
0
(
X˜ei,Xoi
)
Ri(t)Yi(t)
{
dRi(t)Ni(t)−Ri(t)Yi(t)βT
(
X˜ei,Xoi
)
dt−Ri(t)Yi(t)dH0(t)
}
.
Replace the unknown quantity Ri(t) and X˜ei by their consistently estimated version
Rˆi(t) and Xˆei, we can solve the following estimation equation to obtain βˆ
T
= (βˆe, βˆ
T
o).
Denote XIOE =
[
XTeXIo
(
XTIoXIo
)−1
(0p, 0p, Ip)
]
, which is a (p + 1) × (p + 2) matrix.
With known weighting function wi(t),we have
0 =
n∑
i=1
wi(t)Yˆi(t)
{
dNˆi(t)− Yˆi(t)βTXIOEXIoidt− Yˆi(t)dH0(t)
}
0 =
n∑
i=1
∫ τ
0
wi(t)Yˆi(t)XIOEXIoi
{
dNˆi(t)− Yˆi(t)βTXIOEXIoidt− Yˆi(t)dH0(t)
}
.
From the first equation, we obtain
dHˆ0(t) =
∑n
i=1 wi(s)Yˆi(t)
{
dNˆi(t)− Yˆi(t)βTXIOEXIoi
}
∑n
i=1 wi(t)Yˆ
2
i (t)
.
Plug the first equation solution into the second, we have
0 =
n∑
i=1
∫ τ
0
[
XIOE
{
XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
}]
× wi(t)Yˆi(t)
{
dNˆi(t)− Yˆi(t)βTXIOEXIoidt
}
.
C. Zheng et al./Instrumental Variable with Competing Risk Model 7
So we have
βˆ =
n−1 n∑
i=1
∫ τ
0
[
XIOE
{
XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
}]⊗2
wi(t)Yˆ
2
i (t)dt
−1
×
(
n−1
n∑
i=1
∫ τ
0
[
XIOE
{
XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
}]
wi(t)Yˆi(t)dNˆi(t)
)
= S−12n (γˆ, Λˆc)S1n(γˆ, Λˆc)
where a⊗2 = aaT.
The baseline hazard is not identifiable due to the confounding of Xu, i.e., we can
estimate H∗0 (t) =
∫ t
0
h∗0(s)ds but we are not able to estimate H0(t). However, we
are still able to estimate covariate specific subdistribution cumulative incident function
since it can be represented by h∗0(t) instead of h0(t), then we have F1(t|Xe,Xo) = 1−
exp
(
−H∗0 (t)− tβeXe − tβToXo
)
. We can obtain Fˆ1(t|Xe,Xo) = 1−exp
(
−Hˆ∗0 (t)− tβˆeXe − tβˆ
T
oXo
)
with
Hˆ∗0 (t) =
∫ t
0
∑n
i=1 wi(s)Yˆi(s)
{
dNˆi(s)− Yˆi(s)βˆTXIOEXIoids
}
∑n
i=1 wi(s)Yˆ
2
i (s)
To handle the technical difficulty of additive model that the estimated hazard might
not be positive, we use the approach as suggested for the original additive model [14]
by defining a modified version of estimation Hˆ∗mod(t) = max0≤s≤t Hˆ
∗
0 (s). Under
regularity condition, this modified version of Hˆ∗mod(t) is asymptotically equivalent to
Hˆ∗0 (t) and thus we proof the asymptotics results for Hˆ
∗
0 (t).
3. Theoretical Results
We assume the following regularity conditions hold throughout the paper.
Assumption 1: XI , Xu and Xo are mean zero random variables. γTuXu + e is un-
correlated with Xo and XI , i.e., E
(
γTuXu + e|Xo, XI
)
= 0. The variance is
constant, i.e.,
Var
(
γTuXu + e|Xo, XI
)
= σ2.
Assumption 2: The instrumental variableXI is associated withXe conditional onXo
andXu, i.e., αI 6= 0.
Assumption 3: XI is not directly associated with the outcome event, i.e., XI is inde-
pendent of (T, ,Xu) conditional onXo.
Assumption 4: The error term e has mean 0. e is independent of XI ,Xo andXu.
Assumption 5: Xo andXu are independent.
The assumptions above are parallel to the traditional IV assumptions, with the
uncorrelated assumption replaced by independence assumption since our model
is nonlinear. Since we are considering the additive hazard subdistribution model,
we also need the following assumptions related to the additive hazard model.
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Assumption 6: Independent censoring, i.e. C is conditionally independent of (T, ),
conditional on variables XI andXo.
Assumption 7: CovariatesXo, XI ,Xu, Xe have bounded supports and β is an inte-
rior point of the possible parameter space.
Assumption 8: When the time period of interest is [0, τ ], we requireP (C ≥ t|Xo, XI)
to be bounded away from 0 for t ∈ [0, τ ].
Assumption 9: n−1
n∑
i=1
∫ τ
0
[
XIOE
{
XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
}]⊗2
wi(t)Y
∗2
i (t)dt
converge uniformly with probability 1 to a positive definite matrix process Ωτ .
Assumption 10: n−1
n∑
i=1
∫ τ
0
[
XIOE
{
XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
}]⊗2
wi(t)Y
∗2
i (t)dN
∗
i (t)
converges uniformly with probability 1 to a positive definite matrix process Ψτ .
Assumption 11:
σ2β20e
n
n∑
i=1
∫ τ
0
XIOE
[
{XIoi −
{∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
}]
XTIoi
(
XTIoXIo
)−1
XIoi
×
[
XIOE
{
XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
}]T
wi(t)Y
∗2
i (t)dt
converges uniformly with probability 1 to a positive definite matrix process Στ .
Assumption 12: For τ < ∞, there exist bounded continuous functions g(t) and Γ(t)
such that ∥∥∥∥∫ t
0
n−1
∑n
i=1 w
2
i (s)Y
2∗
i (s)dN
∗
i (s)
[n−1
∑n
i=1 wi(s)Y
∗2
i (s)]
2
− g(t)
∥∥∥∥
∞
and ∥∥∥∥∥
∫ t
0
XIOE
∑n
j=1XIojwj(s)Y
∗
j (s)dN
∗
j (s)∑n
j=1 wj(s)Y
∗2
j (s)
− Γ(t)
∥∥∥∥∥
∞
converge to 0 in probability uniformly over t ∈ (0, τ ].
We provide theoretical results in this section with brief proof outline. The technical
details of the proofs can be found in appendix.
Theorem 1: Under assumptions 1-11, βˆ converges to β0 with probability 1.
Proof: Since γˆ and Λˆc converge to γ and Λc uniformly and the regularity conditions
ensure that the function space is in Glivenko Cantelli class, we have βˆ = S−12n (γˆ, Λˆc)S1n(γˆ, Λˆc)
converges to β˜ = S−12n (γ,Λc)S1n(γ,Λc) uniformly with probability 1. By the conver-
gence result for the additive subdistribution hazard model, we know that β˜ converges
to β0 with probability 1. Thus βˆ converges to β0 with probability 1.
For simplicity of the variance form, we will choose Kaplan-Meier estimator for Gˆ(t)
and assume random censoring. In practice, if we believe censoring depends on Xo and
XI , we can model it via certain semiparametric models. Under the correct specification
of such models, the consistency and asymptotic normality results still hold though the
variance will have a more complicated form and the Bootstrap will be recommended
for.
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Theorem 2: Under assumptions 1-11, we have
√
n(βˆ − β0)→d N(0,Ω−1τ (Ψτ + Στ )Ω−1τ )
with influence function Φi as defined in appendix. The variance can be estimated by
using an empirical version of Φˆi of Φi and compute n−1
∑n
i=1 Φ
⊗2
i to estimateEΦ
⊗2
i .
See Appendix for a detailed expression of influence function Φi.
Theorem 3: Under assumptions 1-12, we have
sup
t∈(0,τ ]
|Fˆ1(t|xe,xo)− F1(t|xe,xo)| →p 0
and
√
n(Fˆ1(t|xe,xo)− F1(t|xe,xo)) converges weakly to a mean zero Gaussian pro-
cess with covariance matrix
K(s, t) = (1− F1(t|xe,xo))(1− F1(s|xe,xo))
[g(t ∧ s) + ts(xe,xo)Ω−1τ (Ψτ + Στ )Ω−1τ (xe,xo)T + (xe,xo)Ω−1τ (Γ(t)s+ Γ(s)t)].
4. Simulation
We randomly sample XI from {0, 1} with equal probability. Xo and Xu are sampled
from independent standard normal distributions.Xe is generated asXe = (1, XI , Xo, Xu)γT
with γ = (0, γ2, 0.5,−1). By changing γ2 from 0.2 to 0.4, we mimic the setting with
weak and strong instrumental variables. We vary the sample size n = 100, 400, 1000.
Let t0 = 0.6 be a fixed time point and denote t∗ = min(t, t0). We simulate event time
data from the following subdistribution rate
F (t,  = 1) = 1− {1− p (1− e−t)} exp{−βeXet− βoXot− βuXut}
F (t,  = 2) =
(1− p) (1− e−t) exp{−βeXet∗ − βoXot∗ − βuXut∗}
exp{−βeXet0 − βoXot0 − βuXut0}
In this way, we gaurantee that P ( = 1) = p and P ( = 2) = 1 − p have a sum
F (∞,  = 1) + F (∞,  = 2) = 1 and both F (t,  = 1) and F (t,  = 2) are increasing
functions. We first generate  and then generate T1 and T2 given  by
F (t| = 1) = 1− {1− p(1− e
−t)} exp{−βeXet∗ − βoXot∗ − βuXut∗}
1− (1− p) exp{−βeXet0 − βoXot0 − βuXut0}
F (t| = 2) = exp{−βeXet
∗ − βoXot∗ − βuXut∗}
exp{−βeXet0 − βoXot0 − βuXut0}
We set censoring time as exponentially distributed with parameters set to make 30%
and 50% censoring rate. We set p = 0.8, β = (0.5, 0.2, β3). When setting β3 = 0, we
have the case of no unmeasured confoundings. When setting β3 = 0.2 and 0.4, we have
the cases with weak and strong unmeasured confoundings. The results are summarized
in table 1.
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TABLE 1
Simulation results comparing IV and traditional regression methods in terms of Bias, Standard error (SE),
Coverage rate (CR) of 95% nominal confidence interval under different confounding levels
(none/weak/strong) and IV strength (none/weak/strong).
50% Censoring 30% Censoring
IV method Regression method IV method Regression method
Confounding IV n Bias SE CR Bias SE CR Bias SE CR Bias SE CR
None None 100 5.78 37.62 96% 0.02 0.52 93% 3.96 33.22 97% -0.01 0.41 94%
None None 400 5.62 47.21 97% -0.00 0.24 90% 3.17 37.01 97% -0.01 0.21 92%
None None 1000 -1.75 32.13 97% -0.01 0.13 95% -4.51 25.77 96% -0.01 0.12 95%
None Weak 100 -0.08 1.64 96% -0.01 0.50 92% -0.14 1.37 97% -0.03 0.41 95%
None Weak 400 -0.02 0.63 98% 0.01 0.24 94% 0.02 0.54 98% -0.00 0.20 92%
None Weak 1000 0.07 0.44 93% -0.00 0.13 97% 0.06 0.39 94% -0.01 0.12 94%
None Strong 100 -0.03 0.71 94% -0.02 0.44 94% -0.06 0.57 96% -0.04 0.36 95%
None Strong 400 -0.01 0.32 98% 0.00 0.20 94% 0.02 0.27 98% -0.00 0.17 95%
None Strong 1000 0.03 0.23 95% 0.00 0.12 97% 0.02 0.19 96% 0.00 0.11 95%
Weak None 100 5.66 34.67 96% -0.22 0.55 92% 3.75 32.58 97% -0.23 0.45 90%
Weak None 400 5.61 52.28 97% -0.20 0.28 84% 3.59 33.77 98% -0.21 0.23 82%
Weak None 1000 -1.56 39.24 92% -0.21 0.14 73% -3.90 29.79 93% -0.21 0.13 64%
Weak Weak 100 -0.04 1.74 95% -0.22 0.53 91% -0.08 1.41 96% -0.23 0.44 89%
Weak Weak 400 -0.04 0.69 97% -0.18 0.27 83% 0.02 0.58 98% -0.18 0.23 86%
Weak Weak 1000 0.06 0.50 93% -0.18 0.14 80% 0.05 0.43 94% -0.18 0.13 69%
Weak Strong 100 -0.03 0.77 96% -0.18 0.46 91% -0.04 0.61 98% -0.18 0.39 90%
Weak Strong 400 -0.02 0.35 97% -0.15 0.23 88% 0.01 0.29 97% -0.14 0.19 88%
Weak Strong 1000 0.02 0.25 93% -0.13 0.13 88% 0.02 0.22 95% -0.13 0.12 81%
Strong None 100 3.49 30.60 95% -0.45 0.58 84% 2.48 19.67 96% -0.45 0.48 82%
Strong None 400 4.01 55.30 97% -0.40 0.31 67% 2.10 35.71 97% -0.41 0.26 57%
Strong None 1000 -2.21 41.40 91% -0.41 0.16 28% -4.35 30.16 94% -0.41 0.15 25%
Strong Weak 100 0.08 2.07 96% -0.41 0.57 87% 0.02 1.71 96% -0.41 0.47 84%
Strong Weak 400 -0.02 0.74 97% -0.36 0.30 68% 0.04 0.61 98% -0.36 0.24 64%
Strong Weak 1000 0.03 0.54 91% -0.37 0.16 37% 0.05 0.47 93% -0.36 0.15 27%
Strong Strong 100 0.00 0.89 95% -0.32 0.52 84% -0.02 0.69 96% -0.32 0.42 81%
Strong Strong 400 -0.00 0.38 96% -0.28 0.26 73% 0.02 0.31 98% -0.27 0.22 70%
Strong Strong 1000 0.02 0.28 93% -0.27 0.15 50% 0.03 0.23 94% -0.27 0.13 42%
From the results, we can see that when IV is strong, the IV method has small bias
and correct coverage rate for its 95% nominal confidence interval. However, when IV
becomes weak, the IV estimator performance becomes unsatisfactory, especially in the
small sample size case (i.e. n=100). When IV assumption does not hold and the instru-
mental variable is independent of the exposure, the IV method fails (with very large
bias and variance) as we expected. When IV is strong, we compare the IV method and
the traditional regression method. When there are no unmeasured confoundings, both
methods yield small bias and correct coverage rates for their 95% nominal confidence
interval, although the IV estimator is not as efficient as regression based estimator.
However, as confounding effects increase, we observe the dramatic increase of bias
and smaller coverage rate for regression method while the IV estimator still maintain
small bias and the standard error increases very slightly. The coverage rate is approxi-
mately at its nominal level.
In practice, we recommend first checking whether the IV is strong or not by look-
ing at some ad-hoc statistics from first stage regression model. For example, the F-
statistics>10 is often used in econometric literature [26] as a criteria for strong IV.
When an IV is not very strong while the confounding might be small. The balance-
variance trade-off might favorate using traditional regression method. So we recom-
mend running both models and compare the results. If the two estimators are very
different, then we can see bias in traditional regression method and IV estimator shall
be used. If there are no significant difference between the two, then the traditional re-
gression results could be used while the IV results can be considered as sensitivity
analysis.
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5. Real transplant data example
We now apply the proposed instrumental variable analysis method to a real data ex-
ample. We considered data from the Center for International Blood and Marrow Trans-
plant Research (CIBMTR), on 994 Diffuse Large B Cell Lymphoma (DLBCL) patients,
who are 18 to 76 years old, and had an autologous hematopoietic stem cell transplan-
tation (TX) between 1996 and 2003 [7]. The CIBMTR is comprised of clinical and
basic scientists who share data on their blood and bone marrow transplant patients,
with the CIBMTR Data Collection Center located at the Medical College of Wiscon-
sin. The CIBMTR has a repository of information regarding the results of transplants
at more than 450 transplant centers worldwide. The specific aim of the study was to
compare the clinical outcomes between whether rituximab was (+R cohort, N=176) or
was not (−R cohort, N=818) administered as therapy prior to the transplant. The clini-
cal outcomes compared include relapse/progression of DLBCL, non-relapse mortality
(NRM: defined as death without relapse/progression), progression-free survival (PFS)
and overall survival (OS). Here relapse/progression and NRM are two competing risks.
355 patients were censored at end of study and censoring distribution is independent of
all adjusted covariates by fitting a Cox model for the censoring distribution including
all adjusted covariates (p > 0.10 for each covariate). The CIBMTR study treated the
Year of TX (2000-2003 versus 1996-1999) as a regular covariate which needs to be
adjusted if it is significant in the regression mode, and concluded that pre-TX ritux-
imab did not affect NRM (Hazard Ratio (HR)=0.70, p=0.18) with Year of TX to be
included in the model (HR=0.63, p=0.05).The risk of relapse/progression was lower in
the +R cohort compared to the −R cohort (HR=0.67, p=0.004) without Year of TX to
be included in the final model since it was not significant (HR=0.86, p=0.25).
In the CIBMTR study cohort, there were 18% (174/986) patients who received ritux-
imab in pre-transplant therapy and only 1% (6/482) had rituximab among those trans-
planted prior to 1999. Calendar time (Year of TX) was highly associated with the use of
rituximab since increase in use rituximab was a result of approval by the US Food and
Drug Administrations in 1998. Prior to 1998 Rituximab was available only in clinical
trials. Thus, including calendar time (Year of TX) as a regular covariate in a regression
analysis could lead to a biased conclusion since we cannot estimate the true effect of
rituximab in the presence of Year of TX. Besides observed adjusted covariates (see
[7]), there exist some unobserved covariates, such as molecular subtype of lymphoma
(e.g. germinal center vs. activated B cell vs double hit lymphoma) [27]. These addi-
tional prognostic covariates were unknown at the time that these patients were treated
and the analysis was done. Such unobserved covariates may affect clinical outcomes
and maybe imbalanced between the +R and −R cohorts. In the setting of autologous
transplantation, transplant related mortality is low (< 3% at 1 year) and there were
no major technical improvements during this short time period. Also there were no
major clinical practice changes over this short study time period that would have had
an impact on transplant in lymphoma except the FDA approval of rituximab. So it is
reasonable to assume that the calendar time over such short study time period will not
be associated with any of potential unmeasured confounding variables. We use Year
of TX (before or after the FDA approval the drug) as an instrumental variable (IV) in
proposed IV additive regression model to analyze competing risks data. Risk factors
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TABLE 2
Fitting results for CIBMTR study using traditional regression with “Year of TX" (Model: 1) and without
“Year of TX" (Model: 2) and using “Year of TX" as an instrumental variable (Model: 3). Adjusted
covariates include age, disease status and number of lines of chemotherapy for relapse/progression and
age, time from diagnosis to treatment (DX to TX), Karnofsky Score for NRM.
Outcome Model Variable Coef. Est. (SE) P-value
Relapse 1 Ritux: Yes vs No −.0022 (0.0016) 0.1774
Relapse 1 Age: ≥ 55 vs < 55 0.0033 (0.0015) 0.0320
Relapse 1 Disease Status: Other vs CR1/PIF 0.0065 (0.0015) < .0001
Relapse 1 Prior lines of therapy: > 2 vs ≤ 2 0.0081 (0.0019) < .0001
Relapse 1 Yr of TX: 2000-03 vs 1996-99 −.0035 (0.0015) 0.0162
Relapse 2 Ritux: Yes vs No −.0043 (0.0015) 0.0036
Relapse 2 Age: ≥ 55 vs < 55 0.0033 (0.0016) 0.0346
Relapse 2 Disease Status: Other vs CR1/PIF 0.0067 (0.0015) < .0001
Relapse 2 Prior lines of therapy: > 2 vs ≤ 2 0.0083 (0.0019) < .0001
Relapse 3 Ritux: Yes vs No −.0104 (0.0031) 0.0007
Relapse 3 Age: ≥ 55 vs < 55 0.0038 (0.0016) 0.0175
Relapse 3 Disease Status: Other vs CR1/PIF 0.0063 (0.0015) < .0001
Relapse 3 Prior lines of therapy: > 2 vs ≤ 2 0.0088 (0.0019) < .0001
NRM 1 Ritux: Yes vs No −.0006 (0.0007) 0.3595
NRM 1 Age: ≥ 55 vs < 55 0.0015 (0.0006) 0.0133
NRM 1 Time from DX to TX: > 1 vs ≤ 1 Yr 0.0009 (0.0006) 0.1163
NRM 1 Karnofsky Score: ≥ 90 vs < 90 −.0013 (0.0006) 0.0302
NRM 1 Karnofsky Score: Unknown vs < 90 0.0004 (0.0017) 0.8103
NRM 1 Yr of TX: 2000-03 vs 1996-99 −.0019 (0.0006) 0.0012
NRM 2 Ritux: Yes vs No −.0017 (0.0006) 0.0060
NRM 2 Age: ≥ 55 vs < 55 0.0014 (0.0006) 0.0218
NRM 2 Time from DX to TX: > 1 vs ≤ 1 Yr 0.0009 (0.0006) 0.1307
NRM 2 Karnofsky Score: ≥ 90 vs < 90 −.0013 (0.0006) 0.0328
NRM 2 Karnofsky Score: Unknown vs < 90 −.0006 (0.0016) 0.7263
NRM 3 Ritux: Yes vs No −.0049 (0.0012) < .0001
NRM 3 Age: ≥ 55 vs < 55 0.0018 (0.0006) 0.0040
NRM 3 Time from DX to TX: > 1 vs ≤ 1 Yr 0.0008 (0.0006) 0.1390
NRM 3 Karnofsky Score: ≥ 90 vs < 90 −.0014 (0.0006) 0.0273
NRM 3 Karnofsky Score: Unknown vs < 90 0.0001 (0.0018) 0.9510
adjusted were AGE, Disease Status and Number of Lines of Chemotherapy for
relapse/progression and were AGE, Time from diagnosis (DX) to TX and Karnofsky
Score for NRM. The analysis results for fitting a regular regression including Year of
TX (Model 1), without Year of TX (Model 2), and IV regression analysis (Model 3)
are given in Table 2. When Year of TX was incorrectly to be included in the regression
models, pre-transplant rituximab did not affect both on relapse/progression and NRM
since part of the drug effects were counted by the artificial effect of calendar time of
Year of TX. Without adjusting Year of TX, estimated rituximab effects were underes-
timated, where estimated effect size of rituximab by regular regression compared to IV
analysis were increased from −0.0043 to −0.0104 (relatively, 1.42 times increasing)
for relapse/progression and increased from−0.0017 to−0.0049 (relatively, 1.88 times
increasing) for NRM. Increasing in the size of rituximab effect on the cumulative in-
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cidence function (CIF) can be seen in the plot of predicted CIF for +R cohort versus
−R cohort. At 72 months since TX, the rituximab effect in CIF of relapse/progression
were 20% and 7% by IV regression analysis and by regular regression analysis, re-
spectively (Figure 1). Similarly, the rituximab effect in CIF of NRM were 23% and
8% by IV regression analysis and by regular regression analysis, respectively (Figure
2). We observe significant increase in rituximab effect by IV regression modeling. We
performed a goodness of fit test to check whether all covariates have constant effect
[28]. The test indicates that the main treatment effect has a constant effect (p > 0.1),
and “Disease Status” and “prior lines of therapy" have time-varying effects for relapse.
While for NRM, the main treatment effect has a constant effect and “Time from DX
to TX”, “Karnofsky Score" and “missingness of Karnofsky Score" have time-varying
effects. We considered fitting more flexible models allowing time-varying effects for
covariates that failed the constant effect test. Both models give almost identical results
for the main effect (< 1% difference in estimation). Thus, for the illustrate purpose
we present all results based on constant effect additive model. Another limitation for
the current analysis is that the exposure is binary, while the method require us to fit a
linear model of it. To check whether the linear model approximately hold, we check the
interaction between the binary instrumental variable and other covariates and did not
notice strong interaction, also we performed simulation analysis to check how bias the
result could be if the true model is logistic. From table S1, we could see that the non-
identity link could lead to some bias in the estimator, however it tends to also increase
the variability and the coverage rate is still reasonable.
With calendar time of before or after the FDA approval of rituximab (Year of TX)
as an instrumental variable, we confirmed rituximab effect both on relapse/progression
and NRM. In conclusion, it is important to identify instrumental variable, and to model
and analyze the instrumental variable appropriately in regression analyses.
6. Discussion
Only Kaplan-Meier estimate for the censoring distribution is considered through out
the paper, which requires a strong assumption that censoring time C is independent of
observed covariates. It is clear that this may not be true. He et al. [29] showed that using
covariates adjusted censoring weight can reduce the bias and improve the efficiency in
fitting a proportional subdistribution hazards model when the censoring distribution is
dependent of some covariates. Thus it is useful to generalize the proposed methods and
study the performance by using a regression model for the censoring distribution.
When the exposure is non-gaussian and generalized linear model instead of linear
model holds for the exposure model, the mean-variance relationship will cause the
variance of γTuXu + e depends on XI andXo and thus on X˜e and introduce potential
bias depending on the degree of nonlinearity. When the mean condition holds while the
variance condition not, we will have bias in the second stage estimator from the second
order approximation. However, if the variance is not very sensitive to the mean or the
range of mean is small, the term is still approximately uncorrelated to X˜e and thus the
bias is small, for example in our real data example.
In this paper, we proposed consistent estimators of efficacy of treatment in the pres-
ence of unmeasured confoundings. We showed the asymptotic results of these estima-
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FIGURE 1. Predicted cumulative incidence function of Relapse comparing IV fitting to regular regression
analysis
tors and studied their performance under finite sample size using simulation. The data
example shows that by adjusting unmeasured confounding using instrumental variable,
we are able to identify stronger treatment effects. One limitation of this method is that
due to the nature of additive models, in certain cases it is hard to guarantee the sub-
distribution hazard to be positive. Although it is quite clear in our example that the
approval from FDA will not directly affect the survival outcome, finding a valid instru-
mental variable may be challenging in some other settings. The sensitivity analysis is
required if we are not sure whether the exclusion restriction assumption holds.
Although we assume time-independent effects in our model, the method can be
straightforwardly extended to allow time-varying effects β(t) for the two-stage esti-
mator with a more complicated theoretical variance form. In general we can replace
the two-stage approach by the following one-stage approach:
0 = E[I(T > t,  = 1) exp{−βT(t)(Xe,Xo)}(XI − EXI |Xo)]
Since I(T > t,  = 1) is not always observable due to the censoring, we can use the
IPCW method with weights derived in Zhang et al. [30]. The estimating equation can
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FIGURE 2. Predicted cumulative incidence function of NRM comparing IV fitting to regular regression anal-
ysis
be written as
0 = E[R(t)I(T > t,  = 1) exp{−βT(t)(Xe,Xo)}(XI − EXI |Xo)]
This allows weaker assumptions (i.e. uncorrelated assumption rather than indepen-
dence assumption for XI and outcome conditional on Xe, Xo) and more efficient
results. One the other hand, the advantage of the two-stage approach is computational
and it is easy to be implemented using current available softwares.
In conclusion, the two stage least square estimator is a useful method to handle un-
measured confounding variables for competing risk data analysis and it has good finite
sample size and asymptotic performance. The two stage approach is easy to implement
using available softwares and can be used in various settings including time-varying
effect and time-varying covariateXo. The design of measuring useful instrument vari-
able shall provide us better understanding of the treatment effect under potential con-
founding for compliance.
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Appendix
Proof of Theorem 1:
We first study the behavior of S1n(γˆ, Λˆc). We denote X˜i = (X˜ei,Xoi) and Xˆi =
(Xˆei,Xoi). DenoteM∗i (t) = N
∗
i (t)−
∫ t
0
Y ∗i dHi(t) as an square integrable martingale.
We can rewrite S1n(γˆ, Λˆc) as
S1n(γˆ, Λˆc) = n
−1
n∑
i=1
∫ τ
0
XˆTi − ∑nj=1 XˆTjwj(t)Yˆ 2j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
wi(t)Yˆi(t)dNˆi(t)
= n−1
n∑
i=1
∫ τ
0
XˆTi − ∑nj=1 XˆTjwj(t)Yˆ 2j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
wi(t)Yˆi(t)dM∗i (t)
+n−1
n∑
i=1
∫ τ
0
XˆTi − ∑nj=1 XˆTjwj(t)Yˆ 2j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
wi(t)Yˆi(t)(Rˆi(t)−Ri(t))dNi(t)
= S11n + S12n
For Kaplan Meier estimator, we have
Rˆi(t)−Ri(t) = −G(t)I(Ti < t)
G(Ti)
n∑
j=1
∫ t
Ti
dM cj (u)∑n
k=1 I(Tk ≥ u)
where M cj (u) = I(Ti ≤ u, i = 0) −
∫ u
0
I(Ti ≥ t)dΛc(t). Due to the consistency of
γˆ and uniform convergence of Gˆ(·), we have
S12n = n
−1
n∑
i=1
∫ τ
0
X˜Ti − ∑nj=1 X˜Tjwj(t)Y ∗2j (t)∑n
j=1 wj(t)Y
∗2
j (t)
wi(t)Y ∗i (t)(Rˆi(t)−Ri(t))dNi(t) + op(1)
So we have S12n is an average of martingale integrals with respect to the censoring
filtration Fc(u) = {I(Ti ≤ u, i = 0), I(Ti ≥ t),Xi, i = 1, · · · , n, t ≤ u}. Under
regularity condition, this term is dominated by a bounded function and converge in
probability to 0 uniformly in a compact neighborhood of β0 [31]. Due to the consis-
tency of γˆ and uniform convergence of Gˆ(·), we also haveXˆTi − ∑nj=1 XˆTjwj(t)Yˆ 2j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
wi(t)Yˆi(t) =
X˜Ti − ∑nj=1 X˜Tjwj(t)Y ∗2j (t)∑n
j=1 wj(t)Y
∗2
j (t)
wi(t)Y ∗i (t) + op(1)
So we have
S11n = n
−1
n∑
i=1
∫ τ
0
X˜Ti − ∑nj=1 X˜Tjwj(t)Y ∗2j (t)∑n
j=1 wj(t)Y
∗2
j (t)
wi(t)Y ∗i (t)dM∗i (t) + op(1)
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Due to the consistency of γˆ and uniform convergence of Gˆ(·), we can approximate
S2n(γˆ, Λˆc) by
S2n(γˆ, Λˆc) = n
−1
n∑
i=1
∫ τ
0
X˜Ti − ∑nj=1 X˜Tjwj(t)Y ∗2j (t)∑n
j=1 wj(t)Y
∗2
j (t)
⊗2 wi(t)Y ∗2i (t)dt+ op(1)
Based on the consistency results for traditional additive competing risk model with-
out instrumental variable, β˜ = S2n(γ,Λc)−1S1n(γ,Λc) converge to β0. Since we
have shown that our estimator βˆ − β˜ = op(1), so we obtain the consistency for βˆ.
Proof of Theorem 2:
Denote Un(β) = S2nβ − S1n, we have S2n converge to positive definite matrix Ωτ .
To obtain distribution of βˆ, we know
√
n(βˆ − β0) = A−1τ
√
nUn(β0) + op(1)
So, we just need to provide an expansion of
√
nUn(β0). We have
√
nUn(β0)
= n−1/2
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
)
]
wi(t)Yˆi(t)[dNˆi(t)− Yˆi(t)βT0XIOEXIoidt]
= n−1/2
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
)
]
wi(t)Yˆi(t)dM
∗
i (t)
+n−1/2
n∑
i=1
∫ τ
0
−
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
)
]
wi(t)Yˆ
2
i (t)β
T
0XIOEXIoidt]
+n−1/2
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Yˆ
2
j (t)∑n
j=1 wj(t)Yˆ
2
j (t)
)
]
wi(t)Yˆi(t)[Rˆi(t)−Ri(t)]dMi(t)
= n−1/2
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
wi(t)Y
∗
i (t)dM
∗
i (t)
+n−1/2
n∑
i=1
∫ τ
0
−
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
wi(t)Y
∗2
i (t)β
T
0XIOEXIoidt]
+n−1/2
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
wi(t)Y
∗
i (t)[Rˆi(t)−Ri(t)]dMi(t) + op(1)
= S21n + S22n + S23n
For the first term, it is in the form of martingale integration and we have
S21n = n
−1/2
n∑
i=1
Φ1i(τ) + op(1)
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and
V ar(S21n) = n
−1
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]⊗2
wi(t)Y
∗
i (t)dN
∗
i (t) + op(1)
converge to Ψτ with probability 1.
For the second term, we have
S22n = n
−1/2
n∑
i=1
∫ τ
0
−
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
wi(t)Y
∗2
i (t)β
T
0XIOEXIoidt]
= n−1/2
n∑
i=1
∫ τ
0
−
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
wi(t)Y
∗2
i (t)X
T
IoiX
T
IOEβ0dt]
= n−1/2
n∑
i=1
Φ2i(τ) + op(1)
NoticeXTIOEβ0 = β0e[X
T
IoXIo]
−1XTIoXe, we can approximate S22n by
n−1/2
n∑
i=1
∫ τ
0
−β0e
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
XTIoi[X
T
IoXIo]
−1XTIoXewi(t)Y
∗2
i (t)dt]
V ar(S22n) =
σ2β20e
n
n∑
i=1
∫ τ
0
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]
XTIoi[X
T
IoXIo]
−1XIoi
×
[
XIOE(XIoi −
∑n
j=1XIojwj(t)Y
∗2
j (t)∑n
j=1 wj(t)Y
∗2
j (t)
)
]T
wi(t)Y
∗2
i (t)dt+ op(1)
converge to Στ with probability 1. The covariance between S11n and S22n converge to
0 with probability 1 as in [13].
Now we look at the last term S23n. Under same argument as [20], the empirical
process and Lenglart’s inequality [32] with there approximations provide us
√
nS23n = n
−1/2
n∑
i=1
∫ τ
0
q(u)
pi(u)
dM ci (u) + op(1) = n
−1/2
n∑
i=1
Φ3i(τ),
where
q(u) = −limn→∞n−1
n∑
i=1
∫ τ
0
XIOE(XIoi − ∑nj=1 X˜Tiwi(t)Y ∗2i (t)∑n
j=1 wi(t)Y
∗2
i (t)
)
wi(t)Y ∗i (t)dMi(t)I(t ≥ u ≥ Ti)
pi(u) = limn→∞n−1
n∑
i=1
I(Ti ≥ u)
So the third term variance is 0 and thus is ignorable comparing to the first two terms.
As weighted estimating equation approach, the third term is asymptotically uncorre-
lated with first two terms and thus we obtain the asymptotic variance of the ˆbeta as
Ω−1τ (Ψτ + Στ )Ω
−1
τ with influence function Φi = Φ1i + Φ2i + Φ3i.
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Proof of Theorem 3:
We will first study the performance of− log(1−Fˆ1(t|Xe = xe,Xo = xo)) = Hˆ∗0 (t)+
tβˆT[xe,xo]. We can write this as
n1/2(Hˆ∗0 (t) + tβˆ
T
[xe,xo]−H∗0 (t)− tβT0[xe,xo])
= n1/2(
∫ t
0
∑n
i=1 wi(s)Yˆi(s)[dNˆi(s)− Yˆi(s)βˆ
T
XIOEXIoids]∑n
i=1 wi(s)Yˆ
2
i (s)
−H∗0 (t) + t(βˆ − β0)T[xe,xo])
= n1/2(
∫ t
0
∑n
i=1 wi(s)Y
∗
i (s)[dN
∗
i (s)− Y ∗i (s)βˆ
T
XIOEXIoids]∑n
i=1 wi(s)Y
∗2
i (s)
−H∗0 (t) + t(βˆ − β0)T[xe,xo]) + op(1)
The first term can be written as n−1/2
∑n
i=1 ζ1i with covariance between two time t
and t′ as ∫ t∧t′
0
n−1
∑n
i=1 w
2
i (s)Y
2∗
i (s)dN
∗
i (s)
[n−1
∑n
i=1 wi(s)Y
∗2
i (s)]
2
converge to g(t ∧ t′) in probability uniformly.
The second term has the covariance between two time t and t′ as
tt′(xe,xo)Ω−1τ (Ψτ + Στ )Ω
−1
τ (xe,xo)
T
The covariance between two time t and t′ for first term and second term converge
in probability to
(xe,xo)Ω
−1
τ Γ(t)t
′
So the Martingale Central limit theory provide the asymptotic of− log(1−Fˆ1(t|Xe =
xe,Xo = xo)). Using ∆−method, we can obtian the results in theorem 3.
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Supplement
We studied the effect of first stage model misspecification using parameter estimated
from the real data example (i.e., the survival parameter from model 3 and the logistic
regression parameter from regression Xe on XI and XO) with n = 986. The unmea-
sured confounder is simulated from U(−0.5, 0.5) and the confounding strength are set
the same as the weakest covariate’s effect. Then we use the parameter to simulate Xe,
Y , δ and δ. The result shows that although small bias exists, due to the increase in
variability, the coverage rate is still reasonable.
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TABLE 3
*
Table S1: Simulation results studying IV performance under model misspecification.
Relapse NRM
True Effect Bias SE CR True Effec Bias SE CR
0.0104 0.0031 0.0039 94% 0.0049 0.0001 0.0012 98%
